General
Preferred name
CABOTEGRAVIR
Synonyms
GSK744 ()
GSK-1265744 ()
S/GSK1265744 ()
GSK744 (S/GSK1265744) ()
GSK1265744 ()
Cabotegravir (sodium) ()
GSK-1265744 (sodium) ()
S/GSK1265744 (sodium) ()
GSK744, S/GSK1265744 ()
GSK-1265744 sodium ()
Cabotegravir (GSK1265744) ()
CABOTEGRAVIR SODIUM ()
Cabotegravir component of cabenuva ()
Apretude ()
S-265744 ()
GSK1265744A ()
GSK-1265744A ()
S-265744B ()
GSK-1265744B ()
Vocabria ()
GSK1265744B ()
Cabotegravir-d5 ()
P&D ID
PD012552
CAS
1051375-10-0
1051375-13-3
2750534-77-9
Tags
available
drug
Approved by
PMDA
FDA
EMA
First approval
2020
2021
Drug indication
Human immunodeficiency virus infection
HIV infection
HIV-Associated Lipodystrophy Syndrome
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cabotegravir (GSK1265744, CAB) is a long-acting HIV integrase inhibitor. It is structurally related to . (GtoPdb)
DESCRIPTION Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 ¦ÌM and 0.81 ¦ÌM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS[1][2].
PRICE 38
DESCRIPTION Cabotegravir (GSK-1265744) sodium is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 ¦ÌM and 0.81 ¦ÌM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir sodium can be used to research AIDS[1][2].
DESCRIPTION Cabotegravir (S/GSK1265744) (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor and inhibits the HIV-1 integrase catalyzed strand transfer reaction (IC50: 3.0 nM). (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
18
AdooQ Bioactive Compound Library
A16014
Cayman Chemical Bioactives
27215
31319
ChEMBL Approved Drugs
CHEMBL2403238
CHEMBL3137330
ChEMBL Drugs
CHEMBL2403238
CHEMBL3137330
Drug Repurposing Hub
DrugBank
DB11751
DrugBank Approved Drugs
DB11751
DrugCentral
5440
DrugCentral Approved Drugs
5440
DrugMAP
DMT8J0I
EU-OPENSCREEN Bioactive Compound Library
EOS100194
Guide to Pharmacology
11386
MedChem Express Bioactive Compound Library
HY-15592
HY-15592A
NCATS Inxight Approved Drugs
HMH0132Z1Q
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
cabotegravir-gsk744-gsk1265744
cabotegravir-sodium
TargetMol Bioactive Compound Library
T6098
External IDs
51
Properties
(calculated by RDKit )
Molecular Weight
405.11
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
4
Aromatic Ring Count
2
cLogP
0.96
TPSA
100.87
Fraction CSP3
0.32
Chiral centers
2.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
HIV
HIV Integrase
OAT
Integrase
MOA
HIV integrase inhibitor
Pathway
Microbiology/virology
Proteases/Proteasome
Anti-infection
Membrane Transporter/Ion Channel
Metabolic Enzyme/Protease
Source data